Product name,Alternative name,Product type,Non-traditionals categories,Antibacterial class,Indications,Route of administration,R&D phase,Clinical trials,Developer,Pathogen category,Pathogen name,Pathogen activity,Active against priority pathogens?,Innovative?,Mycobacterium tuberculosis,Clostridioides difficile
Bacteriophage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,NCT04682964,Tashkent Pediatric Medical Institute,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,Yes,NA,NA,NA
Bacteriophage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,NCT04682964,Tashkent Pediatric Medical Institute,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,NA,NA,NA
Bacteriophage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,NCT04682964,Tashkent Pediatric Medical Institute,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,NA,NA,NA
Bacteriophage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,NCT04682964,Tashkent Pediatric Medical Institute,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,NA,NA,NA
Bacteriophage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,NCT04682964,Tashkent Pediatric Medical Institute,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
Bacteriophage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,NCT04682964,Tashkent Pediatric Medical Institute,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
Bacteriophage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,NCT04682964,Tashkent Pediatric Medical Institute,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,NA,NA,NA
Bacteriophage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,NCT04682964,Tashkent Pediatric Medical Institute,Priority pathogens,Enterococcus faecium,Other priority pathogens,Yes,NA,NA,NA
Bacteriophage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,NCT04682964,Tashkent Pediatric Medical Institute,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,NA,NA,NA
Bacteriophage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,NCT04682964,Tashkent Pediatric Medical Institute,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,NA,NA,NA
Bacteriophage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,NCT04682964,Tashkent Pediatric Medical Institute,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
Bacteriophage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,NCT04682964,Tashkent Pediatric Medical Institute,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
Bacteriophage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,NCT04682964,Tashkent Pediatric Medical Institute,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
9MW1411,NA,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,NCT04784312,Mabwell Bioscience,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
9MW1411,NA,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,NCT04784312,Mabwell Bioscience,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,NA,NA,NA
9MW1411,NA,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,NCT04784312,Mabwell Bioscience,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,NA,NA,NA
9MW1411,NA,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,NCT04784312,Mabwell Bioscience,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,NA,NA,NA
9MW1411,NA,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,NCT04784312,Mabwell Bioscience,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
9MW1411,NA,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,NCT04784312,Mabwell Bioscience,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
9MW1411,NA,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,NCT04784312,Mabwell Bioscience,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,NA,NA,NA
9MW1411,NA,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,NCT04784312,Mabwell Bioscience,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
9MW1411,NA,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,NCT04784312,Mabwell Bioscience,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,NA,NA,NA
9MW1411,NA,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,NCT04784312,Mabwell Bioscience,Priority pathogens,Critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
9MW1411,NA,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,NCT04784312,Mabwell Bioscience,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
9MW1411,NA,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,NCT04784312,Mabwell Bioscience,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
9MW1411,NA,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,NCT04784312,Mabwell Bioscience,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
AB103,Reltecimod,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,"NCT02469857, NCT03403751",Atox Bio,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
AB103,Reltecimod,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,"NCT02469857, NCT03403751",Atox Bio,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,NA,NA,NA
AB103,Reltecimod,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,"NCT02469857, NCT03403751",Atox Bio,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,NA,NA,NA
AB103,Reltecimod,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,"NCT02469857, NCT03403751",Atox Bio,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,NA,NA,NA
AB103,Reltecimod,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,"NCT02469857, NCT03403751",Atox Bio,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
AB103,Reltecimod,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,"NCT02469857, NCT03403751",Atox Bio,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
AB103,Reltecimod,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,"NCT02469857, NCT03403751",Atox Bio,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,NA,NA,NA
AB103,Reltecimod,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,"NCT02469857, NCT03403751",Atox Bio,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
AB103,Reltecimod,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,"NCT02469857, NCT03403751",Atox Bio,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,NA,NA,NA
AB103,Reltecimod,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,"NCT02469857, NCT03403751",Atox Bio,Priority pathogens,Critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
AB103,Reltecimod,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,"NCT02469857, NCT03403751",Atox Bio,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
AB103,Reltecimod,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,"NCT02469857, NCT03403751",Atox Bio,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
AB103,Reltecimod,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,"NCT02469857, NCT03403751",Atox Bio,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
Afabicin,Debio 1450,Antibiotics,NA,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,"NCT02426918, NCT03723551",Debiopharm International SA,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,No,Yes,NA,NA
Afabicin,Debio 1450,Antibiotics,NA,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,"NCT02426918, NCT03723551",Debiopharm International SA,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,Yes,NA,NA
Afabicin,Debio 1450,Antibiotics,NA,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,"NCT02426918, NCT03723551",Debiopharm International SA,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,No,Yes,NA,NA
Afabicin,Debio 1450,Antibiotics,NA,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,"NCT02426918, NCT03723551",Debiopharm International SA,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,Yes,NA,NA
Afabicin,Debio 1450,Antibiotics,NA,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,"NCT02426918, NCT03723551",Debiopharm International SA,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,No,Yes,NA,NA
Afabicin,Debio 1450,Antibiotics,NA,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,"NCT02426918, NCT03723551",Debiopharm International SA,Priority pathogens,Helicobacter pylori,Other priority pathogens,No,Yes,NA,NA
Afabicin,Debio 1450,Antibiotics,NA,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,"NCT02426918, NCT03723551",Debiopharm International SA,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,Yes,NA,NA
Afabicin,Debio 1450,Antibiotics,NA,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,"NCT02426918, NCT03723551",Debiopharm International SA,Priority pathogens,Enterococcus faecium,Other priority pathogens,No,Yes,NA,NA
Afabicin,Debio 1450,Antibiotics,NA,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,"NCT02426918, NCT03723551",Debiopharm International SA,Priority pathogens,Enterobacterales,Critical priority pathogens,No,Yes,NA,NA
Afabicin,Debio 1450,Antibiotics,NA,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,"NCT02426918, NCT03723551",Debiopharm International SA,Priority pathogens,Critical priority pathogens,Critical priority pathogens,No,Yes,NA,NA
Afabicin,Debio 1450,Antibiotics,NA,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,"NCT02426918, NCT03723551",Debiopharm International SA,Priority pathogens,Campylobacter spp.,Other priority pathogens,No,Yes,NA,NA
Afabicin,Debio 1450,Antibiotics,NA,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,"NCT02426918, NCT03723551",Debiopharm International SA,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,Yes,NA,NA
Afabicin,Debio 1450,Antibiotics,NA,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,"NCT02426918, NCT03723551",Debiopharm International SA,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,No,Yes,NA,NA
ALS-4,NA,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Not registered,Aptorum Group,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
ALS-4,NA,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Not registered,Aptorum Group,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,NA,NA,NA
ALS-4,NA,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Not registered,Aptorum Group,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,NA,NA,NA
ALS-4,NA,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Not registered,Aptorum Group,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,NA,NA,NA
ALS-4,NA,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Not registered,Aptorum Group,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
ALS-4,NA,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Not registered,Aptorum Group,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
ALS-4,NA,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Not registered,Aptorum Group,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,NA,NA,NA
ALS-4,NA,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Not registered,Aptorum Group,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
ALS-4,NA,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Not registered,Aptorum Group,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,NA,NA,NA
ALS-4,NA,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Not registered,Aptorum Group,Priority pathogens,Critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
ALS-4,NA,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Not registered,Aptorum Group,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
ALS-4,NA,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Not registered,Aptorum Group,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
ALS-4,NA,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Not registered,Aptorum Group,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
AP-PA02,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04596319,Armata Pharmaceuticals,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
AP-PA02,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04596319,Armata Pharmaceuticals,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,NA,NA,NA
AP-PA02,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04596319,Armata Pharmaceuticals,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,NA,NA,NA
AP-PA02,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04596319,Armata Pharmaceuticals,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,NA,NA,NA
AP-PA02,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04596319,Armata Pharmaceuticals,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
AP-PA02,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04596319,Armata Pharmaceuticals,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
AP-PA02,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04596319,Armata Pharmaceuticals,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,NA,NA,NA
AP-PA02,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04596319,Armata Pharmaceuticals,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
AP-PA02,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04596319,Armata Pharmaceuticals,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,NA,NA,NA
AP-PA02,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04596319,Armata Pharmaceuticals,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,NA,NA,NA
AP-PA02,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04596319,Armata Pharmaceuticals,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
AP-PA02,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04596319,Armata Pharmaceuticals,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
AP-PA02,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04596319,Armata Pharmaceuticals,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
AR-301,Tosatoxumab,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,NCT03816956,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
AR-301,Tosatoxumab,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,NCT03816956,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,NA,NA,NA
AR-301,Tosatoxumab,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,NCT03816956,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,NA,NA,NA
AR-301,Tosatoxumab,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,NCT03816956,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Other priority pathogens,Other priority pathogens,NA,NA,NA,NA
AR-301,Tosatoxumab,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,NCT03816956,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
AR-301,Tosatoxumab,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,NCT03816956,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
AR-301,Tosatoxumab,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,NCT03816956,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,NA,NA,NA
AR-301,Tosatoxumab,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,NCT03816956,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
AR-301,Tosatoxumab,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,NCT03816956,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Enterobacterales,Critical priority pathogens,NA,NA,NA,NA
AR-301,Tosatoxumab,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,NCT03816956,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
AR-301,Tosatoxumab,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,NCT03816956,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
AR-301,Tosatoxumab,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,NCT03816956,"Aridis Pharmaceuticals, Inc.",Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
AR-301,Tosatoxumab,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,NCT03816956,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
AR-302,"MEDI-4893, Suvratoxumab",Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,NCT02296320,Aridis AstraZeneca/ MedImmune,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
AR-302,"MEDI-4893, Suvratoxumab",Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,NCT02296320,Aridis AstraZeneca/ MedImmune,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,NA,NA,NA
AR-302,"MEDI-4893, Suvratoxumab",Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,NCT02296320,Aridis AstraZeneca/ MedImmune,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,NA,NA,NA
AR-302,"MEDI-4893, Suvratoxumab",Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,NCT02296320,Aridis AstraZeneca/ MedImmune,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,NA,NA,NA
AR-302,"MEDI-4893, Suvratoxumab",Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,NCT02296320,Aridis AstraZeneca/ MedImmune,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
AR-302,"MEDI-4893, Suvratoxumab",Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,NCT02296320,Aridis AstraZeneca/ MedImmune,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
AR-302,"MEDI-4893, Suvratoxumab",Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,NCT02296320,Aridis AstraZeneca/ MedImmune,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,NA,NA,NA
AR-302,"MEDI-4893, Suvratoxumab",Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,NCT02296320,Aridis AstraZeneca/ MedImmune,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
AR-302,"MEDI-4893, Suvratoxumab",Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,NCT02296320,Aridis AstraZeneca/ MedImmune,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,NA,NA,NA
AR-302,"MEDI-4893, Suvratoxumab",Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,NCT02296320,Aridis AstraZeneca/ MedImmune,Priority pathogens,Critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
AR-302,"MEDI-4893, Suvratoxumab",Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,NCT02296320,Aridis AstraZeneca/ MedImmune,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
AR-302,"MEDI-4893, Suvratoxumab",Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,NCT02296320,Aridis AstraZeneca/ MedImmune,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
AR-302,"MEDI-4893, Suvratoxumab",Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,NCT02296320,Aridis AstraZeneca/ MedImmune,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
ARX-1796,Oral Avibactam prodrug,Antibiotics,NA,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,NCT03931876,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,No,No,NA,NA
ARX-1796,Oral Avibactam prodrug,Antibiotics,NA,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,NCT03931876,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Staphylococcus aureus,Other priority pathogens,No,No,NA,NA
ARX-1796,Oral Avibactam prodrug,Antibiotics,NA,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,NCT03931876,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,NA,NA
ARX-1796,Oral Avibactam prodrug,Antibiotics,NA,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,NCT03931876,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Other priority pathogens,Other priority pathogens,No,No,NA,NA
ARX-1796,Oral Avibactam prodrug,Antibiotics,NA,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,NCT03931876,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,No,No,NA,NA
ARX-1796,Oral Avibactam prodrug,Antibiotics,NA,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,NCT03931876,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Helicobacter pylori,Other priority pathogens,No,No,NA,NA
ARX-1796,Oral Avibactam prodrug,Antibiotics,NA,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,NCT03931876,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,No,No,NA,NA
ARX-1796,Oral Avibactam prodrug,Antibiotics,NA,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,NCT03931876,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Enterococcus faecium,Other priority pathogens,No,No,NA,NA
ARX-1796,Oral Avibactam prodrug,Antibiotics,NA,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,NCT03931876,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,No,NA,NA
ARX-1796,Oral Avibactam prodrug,Antibiotics,NA,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,NCT03931876,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,NA,NA
ARX-1796,Oral Avibactam prodrug,Antibiotics,NA,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,NCT03931876,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Campylobacter spp.,Other priority pathogens,No,No,NA,NA
ARX-1796,Oral Avibactam prodrug,Antibiotics,NA,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,NCT03931876,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,NA,NA
ARX-1796,Oral Avibactam prodrug,Antibiotics,NA,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,NCT03931876,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,No,NA,NA
Benapenem,NA,Antibiotics,NA,Carbapenem,cUTI,IV,Phase III,"NCT03578588, CTR20190760, CTR20181302",Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,No,NA,NA
Benapenem,NA,Antibiotics,NA,Carbapenem,cUTI,IV,Phase III,"NCT03578588, CTR20190760, CTR20181302",Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,No,NA,NA
Benapenem,NA,Antibiotics,NA,Carbapenem,cUTI,IV,Phase III,"NCT03578588, CTR20190760, CTR20181302",Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,NA,NA
Benapenem,NA,Antibiotics,NA,Carbapenem,cUTI,IV,Phase III,"NCT03578588, CTR20190760, CTR20181302",Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,No,NA,NA
Benapenem,NA,Antibiotics,NA,Carbapenem,cUTI,IV,Phase III,"NCT03578588, CTR20190760, CTR20181302",Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,No,NA,NA
Benapenem,NA,Antibiotics,NA,Carbapenem,cUTI,IV,Phase III,"NCT03578588, CTR20190760, CTR20181302",Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,No,NA,NA
Benapenem,NA,Antibiotics,NA,Carbapenem,cUTI,IV,Phase III,"NCT03578588, CTR20190760, CTR20181302",Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,No,NA,NA
Benapenem,NA,Antibiotics,NA,Carbapenem,cUTI,IV,Phase III,"NCT03578588, CTR20190760, CTR20181302",Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,No,NA,NA
Benapenem,NA,Antibiotics,NA,Carbapenem,cUTI,IV,Phase III,"NCT03578588, CTR20190760, CTR20181302",Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,No,NA,NA
Benapenem,NA,Antibiotics,NA,Carbapenem,cUTI,IV,Phase III,"NCT03578588, CTR20190760, CTR20181302",Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,NA,NA
Benapenem,NA,Antibiotics,NA,Carbapenem,cUTI,IV,Phase III,"NCT03578588, CTR20190760, CTR20181302",Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,No,NA,NA
Benapenem,NA,Antibiotics,NA,Carbapenem,cUTI,IV,Phase III,"NCT03578588, CTR20190760, CTR20181302",Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,NA,NA
Benapenem,NA,Antibiotics,NA,Carbapenem,cUTI,IV,Phase III,"NCT03578588, CTR20190760, CTR20181302",Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,No,NA,NA
BWC0977,NA,Antibiotics,NA,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT05088421,Bugworks Research,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,Yes,Inconclusive,NA,NA
BWC0977,NA,Antibiotics,NA,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT05088421,Bugworks Research,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,Inconclusive,NA,NA
BWC0977,NA,Antibiotics,NA,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT05088421,Bugworks Research,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,Inconclusive,NA,NA
BWC0977,NA,Antibiotics,NA,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT05088421,Bugworks Research,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,Inconclusive,NA,NA
BWC0977,NA,Antibiotics,NA,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT05088421,Bugworks Research,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,Inconclusive,NA,NA
BWC0977,NA,Antibiotics,NA,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT05088421,Bugworks Research,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,Inconclusive,NA,NA
BWC0977,NA,Antibiotics,NA,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT05088421,Bugworks Research,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,Inconclusive,NA,NA
BWC0977,NA,Antibiotics,NA,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT05088421,Bugworks Research,Priority pathogens,Enterococcus faecium,Other priority pathogens,Yes,Inconclusive,NA,NA
BWC0977,NA,Antibiotics,NA,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT05088421,Bugworks Research,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,Inconclusive,NA,NA
BWC0977,NA,Antibiotics,NA,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT05088421,Bugworks Research,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Possibly,Inconclusive,NA,NA
BWC0977,NA,Antibiotics,NA,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT05088421,Bugworks Research,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,Inconclusive,NA,NA
BWC0977,NA,Antibiotics,NA,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT05088421,Bugworks Research,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Yes,Inconclusive,NA,NA
BWC0977,NA,Antibiotics,NA,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT05088421,Bugworks Research,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,Inconclusive,NA,NA
BX004-A,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT05010577,BiomX,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
BX004-A,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT05010577,BiomX,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,NA,NA,NA
BX004-A,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT05010577,BiomX,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,NA,NA,NA
BX004-A,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT05010577,BiomX,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,NA,NA,NA
BX004-A,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT05010577,BiomX,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
BX004-A,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT05010577,BiomX,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
BX004-A,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT05010577,BiomX,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,NA,NA,NA
BX004-A,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT05010577,BiomX,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
BX004-A,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT05010577,BiomX,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,NA,NA,NA
BX004-A,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT05010577,BiomX,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,NA,NA,NA
BX004-A,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT05010577,BiomX,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
BX004-A,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT05010577,BiomX,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
BX004-A,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT05010577,BiomX,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
CAL02,NA,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,NCT02583373,Eagle Pharmaceuticals (Combioxin SA),Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,Yes,NA,NA,NA
CAL02,NA,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,NCT02583373,Eagle Pharmaceuticals (Combioxin SA),Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,NA,NA,NA
CAL02,NA,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,NCT02583373,Eagle Pharmaceuticals (Combioxin SA),Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,NA,NA,NA
CAL02,NA,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,NCT02583373,Eagle Pharmaceuticals (Combioxin SA),Priority pathogens,Other priority pathogens,Other priority pathogens,NA,NA,NA,NA
CAL02,NA,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,NCT02583373,Eagle Pharmaceuticals (Combioxin SA),Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
CAL02,NA,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,NCT02583373,Eagle Pharmaceuticals (Combioxin SA),Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
CAL02,NA,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,NCT02583373,Eagle Pharmaceuticals (Combioxin SA),Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,NA,NA,NA
CAL02,NA,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,NCT02583373,Eagle Pharmaceuticals (Combioxin SA),Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
CAL02,NA,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,NCT02583373,Eagle Pharmaceuticals (Combioxin SA),Priority pathogens,Enterobacterales,Critical priority pathogens,NA,NA,NA,NA
CAL02,NA,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,NCT02583373,Eagle Pharmaceuticals (Combioxin SA),Priority pathogens,Critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
CAL02,NA,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,NCT02583373,Eagle Pharmaceuticals (Combioxin SA),Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
CAL02,NA,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,NCT02583373,Eagle Pharmaceuticals (Combioxin SA),Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
CAL02,NA,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,NCT02583373,Eagle Pharmaceuticals (Combioxin SA),Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
CF-301,Exebacase,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,NCT04160468,Contrafect,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
CF-301,Exebacase,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,NCT04160468,Contrafect,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,NA,NA,NA
CF-301,Exebacase,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,NCT04160468,Contrafect,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,NA,NA,NA
CF-301,Exebacase,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,NCT04160468,Contrafect,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,NA,NA,NA
CF-301,Exebacase,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,NCT04160468,Contrafect,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
CF-301,Exebacase,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,NCT04160468,Contrafect,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
CF-301,Exebacase,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,NCT04160468,Contrafect,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,NA,NA,NA
CF-301,Exebacase,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,NCT04160468,Contrafect,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
CF-301,Exebacase,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,NCT04160468,Contrafect,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,NA,NA,NA
CF-301,Exebacase,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,NCT04160468,Contrafect,Priority pathogens,Critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
CF-301,Exebacase,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,NCT04160468,Contrafect,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
CF-301,Exebacase,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,NCT04160468,Contrafect,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
CF-301,Exebacase,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,NCT04160468,Contrafect,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
Delpazolid,LCB01-0371,Antibiotics,NA,Oxazolidinone,"Pulmonary tuberculosis, Gram-positive bacterial infections",Oral,Phase II,"NCT02836483, NCT04550832","LegoChem Biosciences Inc., HaiHe Biopharma",Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,No,y,NA
Durlobactam + sulbactam,ETX2514,Antibiotics,NA,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,"NCT03445195, NCT03894046",Entasis Therapeutics Inc.,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,No,NA,NA
Durlobactam + sulbactam,ETX2514,Antibiotics,NA,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,"NCT03445195, NCT03894046",Entasis Therapeutics Inc.,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,No,NA,NA
Durlobactam + sulbactam,ETX2514,Antibiotics,NA,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,"NCT03445195, NCT03894046",Entasis Therapeutics Inc.,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,NA,NA
Durlobactam + sulbactam,ETX2514,Antibiotics,NA,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,"NCT03445195, NCT03894046",Entasis Therapeutics Inc.,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,No,NA,NA
Durlobactam + sulbactam,ETX2514,Antibiotics,NA,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,"NCT03445195, NCT03894046",Entasis Therapeutics Inc.,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,No,NA,NA
Durlobactam + sulbactam,ETX2514,Antibiotics,NA,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,"NCT03445195, NCT03894046",Entasis Therapeutics Inc.,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,No,NA,NA
Durlobactam + sulbactam,ETX2514,Antibiotics,NA,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,"NCT03445195, NCT03894046",Entasis Therapeutics Inc.,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,No,NA,NA
Durlobactam + sulbactam,ETX2514,Antibiotics,NA,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,"NCT03445195, NCT03894046",Entasis Therapeutics Inc.,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,No,NA,NA
Durlobactam + sulbactam,ETX2514,Antibiotics,NA,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,"NCT03445195, NCT03894046",Entasis Therapeutics Inc.,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,No,NA,NA
Durlobactam + sulbactam,ETX2514,Antibiotics,NA,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,"NCT03445195, NCT03894046",Entasis Therapeutics Inc.,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,NA,NA
Durlobactam + sulbactam,ETX2514,Antibiotics,NA,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,"NCT03445195, NCT03894046",Entasis Therapeutics Inc.,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,No,NA,NA
Durlobactam + sulbactam,ETX2514,Antibiotics,NA,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,"NCT03445195, NCT03894046",Entasis Therapeutics Inc.,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,NA,NA
Durlobactam + sulbactam,ETX2514,Antibiotics,NA,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,"NCT03445195, NCT03894046",Entasis Therapeutics Inc.,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,No,NA,NA
EBL-1003,Apramycin,Antibiotics,NA,Aminoglycoside,Bacterial infections,IV,Phase I,NCT04105205,Juvabis,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,No,NA,NA
EBL-1003,Apramycin,Antibiotics,NA,Aminoglycoside,Bacterial infections,IV,Phase I,NCT04105205,Juvabis,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,No,NA,NA
EBL-1003,Apramycin,Antibiotics,NA,Aminoglycoside,Bacterial infections,IV,Phase I,NCT04105205,Juvabis,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,NA,NA
EBL-1003,Apramycin,Antibiotics,NA,Aminoglycoside,Bacterial infections,IV,Phase I,NCT04105205,Juvabis,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,No,NA,NA
EBL-1003,Apramycin,Antibiotics,NA,Aminoglycoside,Bacterial infections,IV,Phase I,NCT04105205,Juvabis,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,No,NA,NA
EBL-1003,Apramycin,Antibiotics,NA,Aminoglycoside,Bacterial infections,IV,Phase I,NCT04105205,Juvabis,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,No,NA,NA
EBL-1003,Apramycin,Antibiotics,NA,Aminoglycoside,Bacterial infections,IV,Phase I,NCT04105205,Juvabis,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,No,NA,NA
EBL-1003,Apramycin,Antibiotics,NA,Aminoglycoside,Bacterial infections,IV,Phase I,NCT04105205,Juvabis,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,No,NA,NA
EBL-1003,Apramycin,Antibiotics,NA,Aminoglycoside,Bacterial infections,IV,Phase I,NCT04105205,Juvabis,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,No,NA,NA
EBL-1003,Apramycin,Antibiotics,NA,Aminoglycoside,Bacterial infections,IV,Phase I,NCT04105205,Juvabis,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,NA,NA
EBL-1003,Apramycin,Antibiotics,NA,Aminoglycoside,Bacterial infections,IV,Phase I,NCT04105205,Juvabis,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,No,NA,NA
EBL-1003,Apramycin,Antibiotics,NA,Aminoglycoside,Bacterial infections,IV,Phase I,NCT04105205,Juvabis,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,NA,NA
EBL-1003,Apramycin,Antibiotics,NA,Aminoglycoside,Bacterial infections,IV,Phase I,NCT04105205,Juvabis,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,No,NA,NA
Enmetazobactam + cefepime,AAl101 + cefepime,Antibiotics,NA,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,"EudraCT 2017-004868-35, NCT03687255",Allecra therapeutics,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,No,NA,NA
Enmetazobactam + cefepime,AAl101 + cefepime,Antibiotics,NA,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,"EudraCT 2017-004868-35, NCT03687255",Allecra therapeutics,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,No,NA,NA
Enmetazobactam + cefepime,AAl101 + cefepime,Antibiotics,NA,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,"EudraCT 2017-004868-35, NCT03687255",Allecra therapeutics,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,NA,NA
Enmetazobactam + cefepime,AAl101 + cefepime,Antibiotics,NA,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,"EudraCT 2017-004868-35, NCT03687255",Allecra therapeutics,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,No,NA,NA
Enmetazobactam + cefepime,AAl101 + cefepime,Antibiotics,NA,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,"EudraCT 2017-004868-35, NCT03687255",Allecra therapeutics,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,No,NA,NA
Enmetazobactam + cefepime,AAl101 + cefepime,Antibiotics,NA,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,"EudraCT 2017-004868-35, NCT03687255",Allecra therapeutics,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,No,NA,NA
Enmetazobactam + cefepime,AAl101 + cefepime,Antibiotics,NA,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,"EudraCT 2017-004868-35, NCT03687255",Allecra therapeutics,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,No,NA,NA
Enmetazobactam + cefepime,AAl101 + cefepime,Antibiotics,NA,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,"EudraCT 2017-004868-35, NCT03687255",Allecra therapeutics,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,No,NA,NA
Enmetazobactam + cefepime,AAl101 + cefepime,Antibiotics,NA,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,"EudraCT 2017-004868-35, NCT03687255",Allecra therapeutics,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,No,NA,NA
Enmetazobactam + cefepime,AAl101 + cefepime,Antibiotics,NA,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,"EudraCT 2017-004868-35, NCT03687255",Allecra therapeutics,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,No,NA,NA
Enmetazobactam + cefepime,AAl101 + cefepime,Antibiotics,NA,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,"EudraCT 2017-004868-35, NCT03687255",Allecra therapeutics,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,No,NA,NA
Enmetazobactam + cefepime,AAl101 + cefepime,Antibiotics,NA,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,"EudraCT 2017-004868-35, NCT03687255",Allecra therapeutics,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,NA,NA
Enmetazobactam + cefepime,AAl101 + cefepime,Antibiotics,NA,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,"EudraCT 2017-004868-35, NCT03687255",Allecra therapeutics,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,NA,NA
ETX0282 + cefpodoxime,NA,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,NCT03491748,Entasis Therapeutics Inc.,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,No,NA,NA
ETX0282 + cefpodoxime,NA,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,NCT03491748,Entasis Therapeutics Inc.,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,No,NA,NA
ETX0282 + cefpodoxime,NA,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,NCT03491748,Entasis Therapeutics Inc.,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,NA,NA
ETX0282 + cefpodoxime,NA,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,NCT03491748,Entasis Therapeutics Inc.,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,No,NA,NA
ETX0282 + cefpodoxime,NA,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,NCT03491748,Entasis Therapeutics Inc.,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,No,NA,NA
ETX0282 + cefpodoxime,NA,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,NCT03491748,Entasis Therapeutics Inc.,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,No,NA,NA
ETX0282 + cefpodoxime,NA,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,NCT03491748,Entasis Therapeutics Inc.,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,No,NA,NA
ETX0282 + cefpodoxime,NA,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,NCT03491748,Entasis Therapeutics Inc.,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,No,NA,NA
ETX0282 + cefpodoxime,NA,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,NCT03491748,Entasis Therapeutics Inc.,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,No,NA,NA
ETX0282 + cefpodoxime,NA,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,NCT03491748,Entasis Therapeutics Inc.,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,NA,NA
ETX0282 + cefpodoxime,NA,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,NCT03491748,Entasis Therapeutics Inc.,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,No,NA,NA
ETX0282 + cefpodoxime,NA,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,NCT03491748,Entasis Therapeutics Inc.,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,NA,NA
ETX0282 + cefpodoxime,NA,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,NCT03491748,Entasis Therapeutics Inc.,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,No,NA,NA
Ftortiazinon + cefepime,Fluorothyazinone,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,NCT03638830,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
Ftortiazinon + cefepime,Fluorothyazinone,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,NCT03638830,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,NA,NA,NA
Ftortiazinon + cefepime,Fluorothyazinone,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,NCT03638830,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,NA,NA,NA
Ftortiazinon + cefepime,Fluorothyazinone,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,NCT03638830,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,NA,NA,NA
Ftortiazinon + cefepime,Fluorothyazinone,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,NCT03638830,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
Ftortiazinon + cefepime,Fluorothyazinone,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,NCT03638830,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
Ftortiazinon + cefepime,Fluorothyazinone,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,NCT03638830,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,NA,NA,NA
Ftortiazinon + cefepime,Fluorothyazinone,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,NCT03638830,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
Ftortiazinon + cefepime,Fluorothyazinone,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,NCT03638830,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,NA,NA,NA
Ftortiazinon + cefepime,Fluorothyazinone,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,NCT03638830,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,NA,NA,NA
Ftortiazinon + cefepime,Fluorothyazinone,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,NCT03638830,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
Ftortiazinon + cefepime,Fluorothyazinone,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,NCT03638830,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
Ftortiazinon + cefepime,Fluorothyazinone,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,NCT03638830,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
Gepotidacin,GSK2140944,Antibiotics,NA,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,"NCT04010539, NCT04020341",GSK,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,Yes,NA,NA
Gepotidacin,GSK2140944,Antibiotics,NA,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,"NCT04010539, NCT04020341",GSK,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,Yes,NA,NA
Gepotidacin,GSK2140944,Antibiotics,NA,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,"NCT04010539, NCT04020341",GSK,Priority pathogens,Critical priority pathogens,Critical priority pathogens,NA,Yes,NA,NA
Gepotidacin,GSK2140944,Antibiotics,NA,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,"NCT04010539, NCT04020341",GSK,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,Yes,NA,NA
Gepotidacin,GSK2140944,Antibiotics,NA,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,"NCT04010539, NCT04020341",GSK,Priority pathogens,Campylobacter spp.,Other priority pathogens,No,Yes,NA,NA
Gepotidacin,GSK2140944,Antibiotics,NA,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,"NCT04010539, NCT04020341",GSK,Priority pathogens,Enterococcus faecium,Other priority pathogens,No,Yes,NA,NA
Gepotidacin,GSK2140944,Antibiotics,NA,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,"NCT04010539, NCT04020341",GSK,Priority pathogens,Helicobacter pylori,Other priority pathogens,No,Yes,NA,NA
Gepotidacin,GSK2140944,Antibiotics,NA,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,"NCT04010539, NCT04020341",GSK,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,No,Yes,NA,NA
Gepotidacin,GSK2140944,Antibiotics,NA,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,"NCT04010539, NCT04020341",GSK,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,No,Yes,NA,NA
Gepotidacin,GSK2140944,Antibiotics,NA,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,"NCT04010539, NCT04020341",GSK,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,Yes,NA,NA
Gepotidacin,GSK2140944,Antibiotics,NA,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,"NCT04010539, NCT04020341",GSK,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,Yes,Yes,NA,NA
Gepotidacin,GSK2140944,Antibiotics,NA,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,"NCT04010539, NCT04020341",GSK,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,Yes,NA,NA
Gepotidacin,GSK2140944,Antibiotics,NA,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,"NCT04010539, NCT04020341",GSK,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,Yes,NA,NA
GSK3882347,NA,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,NCT04488770,GSK,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
GSK3882347,NA,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,NCT04488770,GSK,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,NA,NA,NA
GSK3882347,NA,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,NCT04488770,GSK,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,NA,NA,NA
GSK3882347,NA,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,NCT04488770,GSK,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,NA,NA,NA
GSK3882347,NA,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,NCT04488770,GSK,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
GSK3882347,NA,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,NCT04488770,GSK,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
GSK3882347,NA,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,NCT04488770,GSK,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,NA,NA,NA
GSK3882347,NA,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,NCT04488770,GSK,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
GSK3882347,NA,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,NCT04488770,GSK,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,NA,NA,NA
GSK3882347,NA,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,NCT04488770,GSK,Priority pathogens,Critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
GSK3882347,NA,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,NCT04488770,GSK,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
GSK3882347,NA,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,NCT04488770,GSK,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
GSK3882347,NA,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,NCT04488770,GSK,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
KBP-7072,NA,Antibiotics,NA,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"NCT02454361, NCT02654626, NCT04532957","KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,No,No,NA,NA
KBP-7072,NA,Antibiotics,NA,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"NCT02454361, NCT02654626, NCT04532957","KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,No,NA,NA
KBP-7072,NA,Antibiotics,NA,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"NCT02454361, NCT02654626, NCT04532957","KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,NA,NA
KBP-7072,NA,Antibiotics,NA,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"NCT02454361, NCT02654626, NCT04532957","KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,No,NA,NA
KBP-7072,NA,Antibiotics,NA,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"NCT02454361, NCT02654626, NCT04532957","KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,No,No,NA,NA
KBP-7072,NA,Antibiotics,NA,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"NCT02454361, NCT02654626, NCT04532957","KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Helicobacter pylori,Other priority pathogens,No,No,NA,NA
KBP-7072,NA,Antibiotics,NA,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"NCT02454361, NCT02654626, NCT04532957","KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,No,NA,NA
KBP-7072,NA,Antibiotics,NA,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"NCT02454361, NCT02654626, NCT04532957","KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Enterococcus faecium,Other priority pathogens,No,No,NA,NA
KBP-7072,NA,Antibiotics,NA,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"NCT02454361, NCT02654626, NCT04532957","KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,No,NA,NA
KBP-7072,NA,Antibiotics,NA,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"NCT02454361, NCT02654626, NCT04532957","KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,NA,NA
KBP-7072,NA,Antibiotics,NA,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"NCT02454361, NCT02654626, NCT04532957","KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Campylobacter spp.,Other priority pathogens,No,No,NA,NA
KBP-7072,NA,Antibiotics,NA,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"NCT02454361, NCT02654626, NCT04532957","KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,NA,NA
KBP-7072,NA,Antibiotics,NA,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"NCT02454361, NCT02654626, NCT04532957","KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,No,NA,NA
LBP-EC01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,NCT04191148,Locus Bioscience,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
LBP-EC01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,NCT04191148,Locus Bioscience,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,NA,NA,NA
LBP-EC01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,NCT04191148,Locus Bioscience,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,NA,NA,NA
LBP-EC01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,NCT04191148,Locus Bioscience,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,NA,NA,NA
LBP-EC01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,NCT04191148,Locus Bioscience,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
LBP-EC01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,NCT04191148,Locus Bioscience,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
LBP-EC01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,NCT04191148,Locus Bioscience,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,NA,NA,NA
LBP-EC01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,NCT04191148,Locus Bioscience,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
LBP-EC01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,NCT04191148,Locus Bioscience,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,NA,NA,NA
LBP-EC01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,NCT04191148,Locus Bioscience,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,NA,NA,NA
LBP-EC01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,NCT04191148,Locus Bioscience,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
LBP-EC01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,NCT04191148,Locus Bioscience,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
LBP-EC01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,NCT04191148,Locus Bioscience,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
LMN-101,NA,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,"NCT04098263, NCT04182490",Lumen Bioscience,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
LMN-101,NA,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,"NCT04098263, NCT04182490",Lumen Bioscience,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,NA,NA,NA
LMN-101,NA,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,"NCT04098263, NCT04182490",Lumen Bioscience,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,NA,NA,NA
LMN-101,NA,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,"NCT04098263, NCT04182490",Lumen Bioscience,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,NA,NA,NA
LMN-101,NA,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,"NCT04098263, NCT04182490",Lumen Bioscience,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
LMN-101,NA,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,"NCT04098263, NCT04182490",Lumen Bioscience,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
LMN-101,NA,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,"NCT04098263, NCT04182490",Lumen Bioscience,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,NA,NA,NA
LMN-101,NA,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,"NCT04098263, NCT04182490",Lumen Bioscience,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
LMN-101,NA,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,"NCT04098263, NCT04182490",Lumen Bioscience,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,NA,NA,NA
LMN-101,NA,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,"NCT04098263, NCT04182490",Lumen Bioscience,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,NA,NA,NA
LMN-101,NA,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,"NCT04098263, NCT04182490",Lumen Bioscience,Priority pathogens,Campylobacter spp.,Other priority pathogens,Yes,NA,NA,NA
LMN-101,NA,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,"NCT04098263, NCT04182490",Lumen Bioscience,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
LMN-101,NA,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,"NCT04098263, NCT04182490",Lumen Bioscience,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
LSVT-1701,"Tonabacase, SAL200",Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,"NCT03089697, NCT03446053",Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
LSVT-1701,"Tonabacase, SAL200",Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,"NCT03089697, NCT03446053",Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,NA,NA,NA
LSVT-1701,"Tonabacase, SAL200",Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,"NCT03089697, NCT03446053",Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,NA,NA,NA
LSVT-1701,"Tonabacase, SAL200",Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,"NCT03089697, NCT03446053",Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,NA,NA,NA
LSVT-1701,"Tonabacase, SAL200",Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,"NCT03089697, NCT03446053",Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
LSVT-1701,"Tonabacase, SAL200",Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,"NCT03089697, NCT03446053",Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
LSVT-1701,"Tonabacase, SAL200",Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,"NCT03089697, NCT03446053",Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,NA,NA,NA
LSVT-1701,"Tonabacase, SAL200",Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,"NCT03089697, NCT03446053",Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
LSVT-1701,"Tonabacase, SAL200",Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,"NCT03089697, NCT03446053",Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,NA,NA,NA
LSVT-1701,"Tonabacase, SAL200",Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,"NCT03089697, NCT03446053",Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
LSVT-1701,"Tonabacase, SAL200",Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,"NCT03089697, NCT03446053",Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
LSVT-1701,"Tonabacase, SAL200",Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,"NCT03089697, NCT03446053",Roivant Sciences/iNtRON Biotechnology,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
LSVT-1701,"Tonabacase, SAL200",Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,"NCT03089697, NCT03446053",Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
MRX-8,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04649541,MicuRx,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,No,NA,NA
MRX-8,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04649541,MicuRx,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,No,NA,NA
MRX-8,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04649541,MicuRx,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,No,NA,NA
MRX-8,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04649541,MicuRx,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,No,NA,NA
MRX-8,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04649541,MicuRx,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,No,NA,NA
MRX-8,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04649541,MicuRx,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,No,NA,NA
MRX-8,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04649541,MicuRx,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,No,NA,NA
MRX-8,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04649541,MicuRx,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,No,NA,NA
MRX-8,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04649541,MicuRx,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,No,NA,NA
MRX-8,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04649541,MicuRx,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,NA,NA
MRX-8,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04649541,MicuRx,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,No,NA,NA
MRX-8,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04649541,MicuRx,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Yes,No,NA,NA
MRX-8,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04649541,MicuRx,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,No,NA,NA
Nacubactam + meropenem,OP0595,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,NCT03174795,Meiji Seika,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,No,NA,NA
Nacubactam + meropenem,OP0595,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,NCT03174795,Meiji Seika,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,No,NA,NA
Nacubactam + meropenem,OP0595,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,NCT03174795,Meiji Seika,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,NA,NA
Nacubactam + meropenem,OP0595,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,NCT03174795,Meiji Seika,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,No,NA,NA
Nacubactam + meropenem,OP0595,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,NCT03174795,Meiji Seika,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,No,NA,NA
Nacubactam + meropenem,OP0595,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,NCT03174795,Meiji Seika,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,No,NA,NA
Nacubactam + meropenem,OP0595,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,NCT03174795,Meiji Seika,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,No,NA,NA
Nacubactam + meropenem,OP0595,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,NCT03174795,Meiji Seika,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,No,NA,NA
Nacubactam + meropenem,OP0595,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,NCT03174795,Meiji Seika,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,No,NA,NA
Nacubactam + meropenem,OP0595,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,NCT03174795,Meiji Seika,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,NA,NA
Nacubactam + meropenem,OP0595,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,NCT03174795,Meiji Seika,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,No,NA,NA
Nacubactam + meropenem,OP0595,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,NCT03174795,Meiji Seika,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,NA,NA
Nacubactam + meropenem,OP0595,Antibiotics,NA,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,NCT03174795,Meiji Seika,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,No,NA,NA
Nafithromycin,WCK 4873,Antibiotics,NA,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,"NCT02903836, CTRI/2019/11/021964",Wockhardt Ltd.,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,No,NA,NA
Nafithromycin,WCK 4873,Antibiotics,NA,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,"NCT02903836, CTRI/2019/11/021964",Wockhardt Ltd.,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,No,NA,NA
Nafithromycin,WCK 4873,Antibiotics,NA,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,"NCT02903836, CTRI/2019/11/021964",Wockhardt Ltd.,Priority pathogens,Critical priority pathogens,Critical priority pathogens,NA,No,NA,NA
Nafithromycin,WCK 4873,Antibiotics,NA,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,"NCT02903836, CTRI/2019/11/021964",Wockhardt Ltd.,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,No,NA,NA
Nafithromycin,WCK 4873,Antibiotics,NA,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,"NCT02903836, CTRI/2019/11/021964",Wockhardt Ltd.,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,No,NA,NA
Nafithromycin,WCK 4873,Antibiotics,NA,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,"NCT02903836, CTRI/2019/11/021964",Wockhardt Ltd.,Priority pathogens,Campylobacter spp.,Other priority pathogens,No,No,NA,NA
Nafithromycin,WCK 4873,Antibiotics,NA,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,"NCT02903836, CTRI/2019/11/021964",Wockhardt Ltd.,Priority pathogens,Enterococcus faecium,Other priority pathogens,No,No,NA,NA
Nafithromycin,WCK 4873,Antibiotics,NA,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,"NCT02903836, CTRI/2019/11/021964",Wockhardt Ltd.,Priority pathogens,Helicobacter pylori,Other priority pathogens,No,No,NA,NA
Nafithromycin,WCK 4873,Antibiotics,NA,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,"NCT02903836, CTRI/2019/11/021964",Wockhardt Ltd.,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,No,No,NA,NA
Nafithromycin,WCK 4873,Antibiotics,NA,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,"NCT02903836, CTRI/2019/11/021964",Wockhardt Ltd.,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,No,NA,NA
Nafithromycin,WCK 4873,Antibiotics,NA,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,"NCT02903836, CTRI/2019/11/021964",Wockhardt Ltd.,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,No,NA,NA
Nafithromycin,WCK 4873,Antibiotics,NA,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,"NCT02903836, CTRI/2019/11/021964",Wockhardt Ltd.,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,No,NA,NA
Nafithromycin,WCK 4873,Antibiotics,NA,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,"NCT02903836, CTRI/2019/11/021964",Wockhardt Ltd.,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,Yes,No,NA,NA
OligoG,CF-5/20,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,NCT03822455,AlgiPharma AS,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
OligoG,CF-5/20,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,NCT03822455,AlgiPharma AS,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,NA,NA,NA
OligoG,CF-5/20,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,NCT03822455,AlgiPharma AS,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,NA,NA,NA
OligoG,CF-5/20,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,NCT03822455,AlgiPharma AS,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,NA,NA,NA
OligoG,CF-5/20,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,NCT03822455,AlgiPharma AS,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
OligoG,CF-5/20,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,NCT03822455,AlgiPharma AS,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
OligoG,CF-5/20,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,NCT03822455,AlgiPharma AS,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,NA,NA,NA
OligoG,CF-5/20,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,NCT03822455,AlgiPharma AS,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
OligoG,CF-5/20,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,NCT03822455,AlgiPharma AS,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,NA,NA,NA
OligoG,CF-5/20,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,NCT03822455,AlgiPharma AS,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,NA,NA,NA
OligoG,CF-5/20,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,NCT03822455,AlgiPharma AS,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
OligoG,CF-5/20,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,NCT03822455,AlgiPharma AS,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
OligoG,CF-5/20,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,NCT03822455,AlgiPharma AS,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
Phage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,NCT04287478,Adaptive Phage Therapeutics,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
Phage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,NCT04287478,Adaptive Phage Therapeutics,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,NA,NA,NA
Phage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,NCT04287478,Adaptive Phage Therapeutics,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,NA,NA,NA
Phage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,NCT04287478,Adaptive Phage Therapeutics,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,NA,NA,NA
Phage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,NCT04287478,Adaptive Phage Therapeutics,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
Phage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,NCT04287478,Adaptive Phage Therapeutics,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
Phage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,NCT04287478,Adaptive Phage Therapeutics,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,NA,NA,NA
Phage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,NCT04287478,Adaptive Phage Therapeutics,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
Phage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,NCT04287478,Adaptive Phage Therapeutics,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,NA,NA,NA
Phage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,NCT04287478,Adaptive Phage Therapeutics,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,NA,NA,NA
Phage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,NCT04287478,Adaptive Phage Therapeutics,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
Phage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,NCT04287478,Adaptive Phage Therapeutics,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
Phage,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,NCT04287478,Adaptive Phage Therapeutics,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
QPX7728 + QPX2014,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,"NCT04380207, NCT05072444",Qpex Biopharma,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2014,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,"NCT04380207, NCT05072444",Qpex Biopharma,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2014,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,"NCT04380207, NCT05072444",Qpex Biopharma,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,Inconclusive,NA,NA
QPX7728 + QPX2014,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,"NCT04380207, NCT05072444",Qpex Biopharma,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2014,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,"NCT04380207, NCT05072444",Qpex Biopharma,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2014,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,"NCT04380207, NCT05072444",Qpex Biopharma,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2014,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,"NCT04380207, NCT05072444",Qpex Biopharma,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2014,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,"NCT04380207, NCT05072444",Qpex Biopharma,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2014,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,"NCT04380207, NCT05072444",Qpex Biopharma,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,Inconclusive,NA,NA
QPX7728 + QPX2014,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,"NCT04380207, NCT05072444",Qpex Biopharma,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,Inconclusive,NA,NA
QPX7728 + QPX2014,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,"NCT04380207, NCT05072444",Qpex Biopharma,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2014,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,"NCT04380207, NCT05072444",Qpex Biopharma,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Yes,Inconclusive,NA,NA
QPX7728 + QPX2014,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,"NCT04380207, NCT05072444",Qpex Biopharma,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,Inconclusive,NA,NA
QPX7728 + QPX2015,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,NCT03939429,Qpex Biopharma,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2015,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,NCT03939429,Qpex Biopharma,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2015,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,NCT03939429,Qpex Biopharma,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,Inconclusive,NA,NA
QPX7728 + QPX2015,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,NCT03939429,Qpex Biopharma,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2015,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,NCT03939429,Qpex Biopharma,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2015,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,NCT03939429,Qpex Biopharma,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2015,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,NCT03939429,Qpex Biopharma,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2015,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,NCT03939429,Qpex Biopharma,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2015,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,NCT03939429,Qpex Biopharma,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,Inconclusive,NA,NA
QPX7728 + QPX2015,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,NCT03939429,Qpex Biopharma,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,Inconclusive,NA,NA
QPX7728 + QPX2015,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,NCT03939429,Qpex Biopharma,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,Inconclusive,NA,NA
QPX7728 + QPX2015,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,NCT03939429,Qpex Biopharma,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Possibly,Inconclusive,NA,NA
QPX7728 + QPX2015,NA,Antibiotics,NA,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,NCT03939429,Qpex Biopharma,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,Inconclusive,NA,NA
QPX9003,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04808414,Qpex Biopharma,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,Inconclusive,NA,NA
QPX9003,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04808414,Qpex Biopharma,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,Inconclusive,NA,NA
QPX9003,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04808414,Qpex Biopharma,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,Inconclusive,NA,NA
QPX9003,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04808414,Qpex Biopharma,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,Inconclusive,NA,NA
QPX9003,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04808414,Qpex Biopharma,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,Inconclusive,NA,NA
QPX9003,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04808414,Qpex Biopharma,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,Inconclusive,NA,NA
QPX9003,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04808414,Qpex Biopharma,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,Inconclusive,NA,NA
QPX9003,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04808414,Qpex Biopharma,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,Inconclusive,NA,NA
QPX9003,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04808414,Qpex Biopharma,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,Inconclusive,NA,NA
QPX9003,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04808414,Qpex Biopharma,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Possibly,Inconclusive,NA,NA
QPX9003,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04808414,Qpex Biopharma,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,Inconclusive,NA,NA
QPX9003,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04808414,Qpex Biopharma,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Possibly,Inconclusive,NA,NA
QPX9003,NA,Antibiotics,NA,Polymyxin,Gram-negative infections,IV,Phase I,NCT04808414,Qpex Biopharma,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,Inconclusive,NA,NA
RG6006,Abx MCP,Antibiotics,NA,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Not registered,Roche,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,Inconclusive,NA,NA
RG6006,Abx MCP,Antibiotics,NA,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Not registered,Roche,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,Inconclusive,NA,NA
RG6006,Abx MCP,Antibiotics,NA,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Not registered,Roche,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,Inconclusive,NA,NA
RG6006,Abx MCP,Antibiotics,NA,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Not registered,Roche,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,Inconclusive,NA,NA
RG6006,Abx MCP,Antibiotics,NA,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Not registered,Roche,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,Inconclusive,NA,NA
RG6006,Abx MCP,Antibiotics,NA,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Not registered,Roche,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,Inconclusive,NA,NA
RG6006,Abx MCP,Antibiotics,NA,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Not registered,Roche,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,Inconclusive,NA,NA
RG6006,Abx MCP,Antibiotics,NA,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Not registered,Roche,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,Inconclusive,NA,NA
RG6006,Abx MCP,Antibiotics,NA,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Not registered,Roche,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,Inconclusive,NA,NA
RG6006,Abx MCP,Antibiotics,NA,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Not registered,Roche,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Possibly,Inconclusive,NA,NA
RG6006,Abx MCP,Antibiotics,NA,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Not registered,Roche,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,Inconclusive,NA,NA
RG6006,Abx MCP,Antibiotics,NA,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Not registered,Roche,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,Inconclusive,NA,NA
RG6006,Abx MCP,Antibiotics,NA,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Not registered,Roche,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,Inconclusive,NA,NA
Rhu-pGSN,Rhu-plasma gelsolin,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,"NCT03466073, NCT04358406",BioAegis Therapeutics,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,Yes,NA,NA,NA
Rhu-pGSN,Rhu-plasma gelsolin,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,"NCT03466073, NCT04358406",BioAegis Therapeutics,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,NA,NA,NA
Rhu-pGSN,Rhu-plasma gelsolin,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,"NCT03466073, NCT04358406",BioAegis Therapeutics,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,NA,NA,NA
Rhu-pGSN,Rhu-plasma gelsolin,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,"NCT03466073, NCT04358406",BioAegis Therapeutics,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,NA,NA,NA
Rhu-pGSN,Rhu-plasma gelsolin,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,"NCT03466073, NCT04358406",BioAegis Therapeutics,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,Yes,NA,NA,NA
Rhu-pGSN,Rhu-plasma gelsolin,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,"NCT03466073, NCT04358406",BioAegis Therapeutics,Priority pathogens,Helicobacter pylori,Other priority pathogens,Yes,NA,NA,NA
Rhu-pGSN,Rhu-plasma gelsolin,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,"NCT03466073, NCT04358406",BioAegis Therapeutics,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,NA,NA,NA
Rhu-pGSN,Rhu-plasma gelsolin,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,"NCT03466073, NCT04358406",BioAegis Therapeutics,Priority pathogens,Enterococcus faecium,Other priority pathogens,Yes,NA,NA,NA
Rhu-pGSN,Rhu-plasma gelsolin,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,"NCT03466073, NCT04358406",BioAegis Therapeutics,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,NA,NA,NA
Rhu-pGSN,Rhu-plasma gelsolin,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,"NCT03466073, NCT04358406",BioAegis Therapeutics,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,NA,NA,NA
Rhu-pGSN,Rhu-plasma gelsolin,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,"NCT03466073, NCT04358406",BioAegis Therapeutics,Priority pathogens,Campylobacter spp.,Other priority pathogens,Yes,NA,NA,NA
Rhu-pGSN,Rhu-plasma gelsolin,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,"NCT03466073, NCT04358406",BioAegis Therapeutics,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Yes,NA,NA,NA
Rhu-pGSN,Rhu-plasma gelsolin,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,"NCT03466073, NCT04358406",BioAegis Therapeutics,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,NA,NA,NA
Solithromycin,T-4288,Antibiotics,NA,Macrolide,S. pneumoniae,IV & oral,Preregistration,JapicCTI163439,Fujfilm Toyama Chemical,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,Yes,No,NA,NA
Solithromycin,T-4288,Antibiotics,NA,Macrolide,S. pneumoniae,IV & oral,Preregistration,JapicCTI163439,Fujfilm Toyama Chemical,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,No,NA,NA
Solithromycin,T-4288,Antibiotics,NA,Macrolide,S. pneumoniae,IV & oral,Preregistration,JapicCTI163439,Fujfilm Toyama Chemical,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,No,NA,NA
Solithromycin,T-4288,Antibiotics,NA,Macrolide,S. pneumoniae,IV & oral,Preregistration,JapicCTI163439,Fujfilm Toyama Chemical,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,No,NA,NA
Solithromycin,T-4288,Antibiotics,NA,Macrolide,S. pneumoniae,IV & oral,Preregistration,JapicCTI163439,Fujfilm Toyama Chemical,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,No,NA,NA
Solithromycin,T-4288,Antibiotics,NA,Macrolide,S. pneumoniae,IV & oral,Preregistration,JapicCTI163439,Fujfilm Toyama Chemical,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,No,NA,NA
Solithromycin,T-4288,Antibiotics,NA,Macrolide,S. pneumoniae,IV & oral,Preregistration,JapicCTI163439,Fujfilm Toyama Chemical,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,No,NA,NA
Solithromycin,T-4288,Antibiotics,NA,Macrolide,S. pneumoniae,IV & oral,Preregistration,JapicCTI163439,Fujfilm Toyama Chemical,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,No,NA,NA
Solithromycin,T-4288,Antibiotics,NA,Macrolide,S. pneumoniae,IV & oral,Preregistration,JapicCTI163439,Fujfilm Toyama Chemical,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,No,NA,NA
Solithromycin,T-4288,Antibiotics,NA,Macrolide,S. pneumoniae,IV & oral,Preregistration,JapicCTI163439,Fujfilm Toyama Chemical,Priority pathogens,Critical priority pathogens,Critical priority pathogens,NA,No,NA,NA
Solithromycin,T-4288,Antibiotics,NA,Macrolide,S. pneumoniae,IV & oral,Preregistration,JapicCTI163439,Fujfilm Toyama Chemical,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,No,NA,NA
Solithromycin,T-4288,Antibiotics,NA,Macrolide,S. pneumoniae,IV & oral,Preregistration,JapicCTI163439,Fujfilm Toyama Chemical,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,No,NA,NA
Solithromycin,T-4288,Antibiotics,NA,Macrolide,S. pneumoniae,IV & oral,Preregistration,JapicCTI163439,Fujfilm Toyama Chemical,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,No,NA,NA
SPR-206,NA,Antibiotics,NA,Polymyxin,Acinetobacter infections,IV,Phase I,NCT04865393,Spero Therapeutics,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,No,NA,NA
SPR-206,NA,Antibiotics,NA,Polymyxin,Acinetobacter infections,IV,Phase I,NCT04865393,Spero Therapeutics,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,No,NA,NA
SPR-206,NA,Antibiotics,NA,Polymyxin,Acinetobacter infections,IV,Phase I,NCT04865393,Spero Therapeutics,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,No,NA,NA
SPR-206,NA,Antibiotics,NA,Polymyxin,Acinetobacter infections,IV,Phase I,NCT04865393,Spero Therapeutics,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,No,NA,NA
SPR-206,NA,Antibiotics,NA,Polymyxin,Acinetobacter infections,IV,Phase I,NCT04865393,Spero Therapeutics,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,No,NA,NA
SPR-206,NA,Antibiotics,NA,Polymyxin,Acinetobacter infections,IV,Phase I,NCT04865393,Spero Therapeutics,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,No,NA,NA
SPR-206,NA,Antibiotics,NA,Polymyxin,Acinetobacter infections,IV,Phase I,NCT04865393,Spero Therapeutics,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,No,NA,NA
SPR-206,NA,Antibiotics,NA,Polymyxin,Acinetobacter infections,IV,Phase I,NCT04865393,Spero Therapeutics,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,No,NA,NA
SPR-206,NA,Antibiotics,NA,Polymyxin,Acinetobacter infections,IV,Phase I,NCT04865393,Spero Therapeutics,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,No,NA,NA
SPR-206,NA,Antibiotics,NA,Polymyxin,Acinetobacter infections,IV,Phase I,NCT04865393,Spero Therapeutics,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,NA,NA
SPR-206,NA,Antibiotics,NA,Polymyxin,Acinetobacter infections,IV,Phase I,NCT04865393,Spero Therapeutics,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,No,NA,NA
SPR-206,NA,Antibiotics,NA,Polymyxin,Acinetobacter infections,IV,Phase I,NCT04865393,Spero Therapeutics,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,No,NA,NA
SPR-206,NA,Antibiotics,NA,Polymyxin,Acinetobacter infections,IV,Phase I,NCT04865393,Spero Therapeutics,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,No,NA,NA
"Sulopenem, sulopenem etzadroxil/probenecid",PF-03709270,Antibiotics,NA,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,"NCT03354598, NCT03357614, NCT03358576",Iterum Therapeutics,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,No,NA,NA
"Sulopenem, sulopenem etzadroxil/probenecid",PF-03709270,Antibiotics,NA,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,"NCT03354598, NCT03357614, NCT03358576",Iterum Therapeutics,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,No,NA,NA
"Sulopenem, sulopenem etzadroxil/probenecid",PF-03709270,Antibiotics,NA,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,"NCT03354598, NCT03357614, NCT03358576",Iterum Therapeutics,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,NA,NA
"Sulopenem, sulopenem etzadroxil/probenecid",PF-03709270,Antibiotics,NA,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,"NCT03354598, NCT03357614, NCT03358576",Iterum Therapeutics,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,No,NA,NA
"Sulopenem, sulopenem etzadroxil/probenecid",PF-03709270,Antibiotics,NA,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,"NCT03354598, NCT03357614, NCT03358576",Iterum Therapeutics,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,No,NA,NA
"Sulopenem, sulopenem etzadroxil/probenecid",PF-03709270,Antibiotics,NA,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,"NCT03354598, NCT03357614, NCT03358576",Iterum Therapeutics,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,No,NA,NA
"Sulopenem, sulopenem etzadroxil/probenecid",PF-03709270,Antibiotics,NA,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,"NCT03354598, NCT03357614, NCT03358576",Iterum Therapeutics,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,No,NA,NA
"Sulopenem, sulopenem etzadroxil/probenecid",PF-03709270,Antibiotics,NA,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,"NCT03354598, NCT03357614, NCT03358576",Iterum Therapeutics,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,No,NA,NA
"Sulopenem, sulopenem etzadroxil/probenecid",PF-03709270,Antibiotics,NA,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,"NCT03354598, NCT03357614, NCT03358576",Iterum Therapeutics,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,No,NA,NA
"Sulopenem, sulopenem etzadroxil/probenecid",PF-03709270,Antibiotics,NA,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,"NCT03354598, NCT03357614, NCT03358576",Iterum Therapeutics,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,NA,NA
"Sulopenem, sulopenem etzadroxil/probenecid",PF-03709270,Antibiotics,NA,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,"NCT03354598, NCT03357614, NCT03358576",Iterum Therapeutics,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,No,NA,NA
"Sulopenem, sulopenem etzadroxil/probenecid",PF-03709270,Antibiotics,NA,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,"NCT03354598, NCT03357614, NCT03358576",Iterum Therapeutics,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,NA,NA
"Sulopenem, sulopenem etzadroxil/probenecid",PF-03709270,Antibiotics,NA,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,"NCT03354598, NCT03357614, NCT03358576",Iterum Therapeutics,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,No,NA,NA
SVT-1C469,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,ACTRN12620000923965,Servatus,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
SVT-1C469,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,ACTRN12620000923965,Servatus,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,NA,NA,NA
SVT-1C469,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,ACTRN12620000923965,Servatus,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,NA,NA,NA
SVT-1C469,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,ACTRN12620000923965,Servatus,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,NA,NA,NA
SVT-1C469,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,ACTRN12620000923965,Servatus,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
SVT-1C469,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,ACTRN12620000923965,Servatus,Priority pathogens,Helicobacter pylori,Other priority pathogens,Yes,NA,NA,NA
SVT-1C469,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,ACTRN12620000923965,Servatus,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,NA,NA,NA
SVT-1C469,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,ACTRN12620000923965,Servatus,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
SVT-1C469,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,ACTRN12620000923965,Servatus,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,NA,NA,NA
SVT-1C469,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,ACTRN12620000923965,Servatus,Priority pathogens,Critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
SVT-1C469,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,ACTRN12620000923965,Servatus,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
SVT-1C469,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,ACTRN12620000923965,Servatus,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
SVT-1C469,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,ACTRN12620000923965,Servatus,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
Taniborbactam + cefepime,VNRX-5133 + cefepime,Antibiotics,NA,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,NCT03840148,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,Yes,NA,NA
Taniborbactam + cefepime,VNRX-5133 + cefepime,Antibiotics,NA,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,NCT03840148,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,Yes,NA,NA
Taniborbactam + cefepime,VNRX-5133 + cefepime,Antibiotics,NA,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,NCT03840148,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,Yes,NA,NA
Taniborbactam + cefepime,VNRX-5133 + cefepime,Antibiotics,NA,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,NCT03840148,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Other priority pathogens,Other priority pathogens,NA,Yes,NA,NA
Taniborbactam + cefepime,VNRX-5133 + cefepime,Antibiotics,NA,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,NCT03840148,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,Yes,NA,NA
Taniborbactam + cefepime,VNRX-5133 + cefepime,Antibiotics,NA,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,NCT03840148,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,Yes,NA,NA
Taniborbactam + cefepime,VNRX-5133 + cefepime,Antibiotics,NA,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,NCT03840148,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,Yes,NA,NA
Taniborbactam + cefepime,VNRX-5133 + cefepime,Antibiotics,NA,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,NCT03840148,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,Yes,NA,NA
Taniborbactam + cefepime,VNRX-5133 + cefepime,Antibiotics,NA,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,NCT03840148,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,Yes,NA,NA
Taniborbactam + cefepime,VNRX-5133 + cefepime,Antibiotics,NA,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,NCT03840148,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,Yes,NA,NA
Taniborbactam + cefepime,VNRX-5133 + cefepime,Antibiotics,NA,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,NCT03840148,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,Yes,NA,NA
Taniborbactam + cefepime,VNRX-5133 + cefepime,Antibiotics,NA,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,NCT03840148,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,Yes,NA,NA
Taniborbactam + cefepime,VNRX-5133 + cefepime,Antibiotics,NA,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,NCT03840148,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,Yes,NA,NA
TNP-2092,NA,Antibiotics,NA,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,NCT03964493,Tennor Therapeutics,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,No,NA,NA
TNP-2092,NA,Antibiotics,NA,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,NCT03964493,Tennor Therapeutics,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Possibly,No,NA,NA
TNP-2092,NA,Antibiotics,NA,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,NCT03964493,Tennor Therapeutics,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,No,No,NA,NA
TNP-2092,NA,Antibiotics,NA,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,NCT03964493,Tennor Therapeutics,Priority pathogens,Other priority pathogens,Other priority pathogens,Possibly,No,NA,NA
TNP-2092,NA,Antibiotics,NA,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,NCT03964493,Tennor Therapeutics,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,No,No,NA,NA
TNP-2092,NA,Antibiotics,NA,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,NCT03964493,Tennor Therapeutics,Priority pathogens,Helicobacter pylori,Other priority pathogens,Possibly,No,NA,NA
TNP-2092,NA,Antibiotics,NA,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,NCT03964493,Tennor Therapeutics,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Possibly,No,NA,NA
TNP-2092,NA,Antibiotics,NA,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,NCT03964493,Tennor Therapeutics,Priority pathogens,Enterococcus faecium,Other priority pathogens,Possibly,No,NA,NA
TNP-2092,NA,Antibiotics,NA,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,NCT03964493,Tennor Therapeutics,Priority pathogens,Enterobacterales,Critical priority pathogens,No,No,NA,NA
TNP-2092,NA,Antibiotics,NA,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,NCT03964493,Tennor Therapeutics,Priority pathogens,Critical priority pathogens,Critical priority pathogens,No,No,NA,NA
TNP-2092,NA,Antibiotics,NA,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,NCT03964493,Tennor Therapeutics,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,No,NA,NA
TNP-2092,NA,Antibiotics,NA,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,NCT03964493,Tennor Therapeutics,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,NA,NA
TNP-2092,NA,Antibiotics,NA,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,NCT03964493,Tennor Therapeutics,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,No,No,NA,NA
TNP-2198,NA,Antibiotics,NA,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,CTR20190734,TenNor Therapeutics,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,No,NA,NA
TNP-2198,NA,Antibiotics,NA,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,CTR20190734,TenNor Therapeutics,Priority pathogens,Staphylococcus aureus,Other priority pathogens,No,No,NA,NA
TNP-2198,NA,Antibiotics,NA,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,CTR20190734,TenNor Therapeutics,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,NA,No,NA,NA
TNP-2198,NA,Antibiotics,NA,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,CTR20190734,TenNor Therapeutics,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,No,NA,NA
TNP-2198,NA,Antibiotics,NA,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,CTR20190734,TenNor Therapeutics,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,Possibly,No,NA,NA
TNP-2198,NA,Antibiotics,NA,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,CTR20190734,TenNor Therapeutics,Priority pathogens,Helicobacter pylori,Other priority pathogens,Yes,No,NA,NA
TNP-2198,NA,Antibiotics,NA,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,CTR20190734,TenNor Therapeutics,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,No,No,NA,NA
TNP-2198,NA,Antibiotics,NA,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,CTR20190734,TenNor Therapeutics,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,No,NA,NA
TNP-2198,NA,Antibiotics,NA,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,CTR20190734,TenNor Therapeutics,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,No,NA,NA
TNP-2198,NA,Antibiotics,NA,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,CTR20190734,TenNor Therapeutics,Priority pathogens,Critical priority pathogens,Critical priority pathogens,NA,No,NA,NA
TNP-2198,NA,Antibiotics,NA,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,CTR20190734,TenNor Therapeutics,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,No,NA,NA
TNP-2198,NA,Antibiotics,NA,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,CTR20190734,TenNor Therapeutics,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,No,NA,NA
TNP-2198,NA,Antibiotics,NA,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,CTR20190734,TenNor Therapeutics,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,No,NA,NA
TRL1068,NA,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT04763759,Trellis Bioscience,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,Yes,NA,NA,NA
TRL1068,NA,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT04763759,Trellis Bioscience,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,NA,NA,NA
TRL1068,NA,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT04763759,Trellis Bioscience,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,NA,NA,NA
TRL1068,NA,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT04763759,Trellis Bioscience,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,NA,NA,NA
TRL1068,NA,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT04763759,Trellis Bioscience,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,Yes,NA,NA,NA
TRL1068,NA,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT04763759,Trellis Bioscience,Priority pathogens,Helicobacter pylori,Other priority pathogens,Possibly,NA,NA,NA
TRL1068,NA,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT04763759,Trellis Bioscience,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,NA,NA,NA
TRL1068,NA,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT04763759,Trellis Bioscience,Priority pathogens,Enterococcus faecium,Other priority pathogens,Yes,NA,NA,NA
TRL1068,NA,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT04763759,Trellis Bioscience,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,NA,NA,NA
TRL1068,NA,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT04763759,Trellis Bioscience,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,NA,NA,NA
TRL1068,NA,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT04763759,Trellis Bioscience,Priority pathogens,Campylobacter spp.,Other priority pathogens,Possibly,NA,NA,NA
TRL1068,NA,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT04763759,Trellis Bioscience,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Yes,NA,NA,NA
TRL1068,NA,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,NCT04763759,Trellis Bioscience,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,NA,NA,NA
TXA709,NA,Antibiotics,NA,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,Not registered,TAXIS Pharmaceuticals,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,No,Yes,NA,NA
TXA709,NA,Antibiotics,NA,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,Not registered,TAXIS Pharmaceuticals,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,Yes,NA,NA
TXA709,NA,Antibiotics,NA,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,Not registered,TAXIS Pharmaceuticals,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,No,Yes,NA,NA
TXA709,NA,Antibiotics,NA,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,Not registered,TAXIS Pharmaceuticals,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,Yes,NA,NA
TXA709,NA,Antibiotics,NA,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,Not registered,TAXIS Pharmaceuticals,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,No,Yes,NA,NA
TXA709,NA,Antibiotics,NA,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,Not registered,TAXIS Pharmaceuticals,Priority pathogens,Helicobacter pylori,Other priority pathogens,No,Yes,NA,NA
TXA709,NA,Antibiotics,NA,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,Not registered,TAXIS Pharmaceuticals,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,Yes,NA,NA
TXA709,NA,Antibiotics,NA,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,Not registered,TAXIS Pharmaceuticals,Priority pathogens,Enterococcus faecium,Other priority pathogens,No,Yes,NA,NA
TXA709,NA,Antibiotics,NA,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,Not registered,TAXIS Pharmaceuticals,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,Yes,NA,NA
TXA709,NA,Antibiotics,NA,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,Not registered,TAXIS Pharmaceuticals,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,Yes,NA,NA
TXA709,NA,Antibiotics,NA,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,Not registered,TAXIS Pharmaceuticals,Priority pathogens,Campylobacter spp.,Other priority pathogens,No,Yes,NA,NA
TXA709,NA,Antibiotics,NA,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,Not registered,TAXIS Pharmaceuticals,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,Yes,NA,NA
TXA709,NA,Antibiotics,NA,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,Not registered,TAXIS Pharmaceuticals,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,Yes,NA,NA
VNRX-7145 + ceftibuten,NA,Antibiotics,NA,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,NCT04243863,Venatorx,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,Yes,NA,NA
VNRX-7145 + ceftibuten,NA,Antibiotics,NA,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,NCT04243863,Venatorx,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,Yes,NA,NA
VNRX-7145 + ceftibuten,NA,Antibiotics,NA,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,NCT04243863,Venatorx,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,Yes,NA,NA
VNRX-7145 + ceftibuten,NA,Antibiotics,NA,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,NCT04243863,Venatorx,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,Yes,NA,NA
VNRX-7145 + ceftibuten,NA,Antibiotics,NA,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,NCT04243863,Venatorx,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,Yes,NA,NA
VNRX-7145 + ceftibuten,NA,Antibiotics,NA,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,NCT04243863,Venatorx,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,Yes,NA,NA
VNRX-7145 + ceftibuten,NA,Antibiotics,NA,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,NCT04243863,Venatorx,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,Yes,NA,NA
VNRX-7145 + ceftibuten,NA,Antibiotics,NA,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,NCT04243863,Venatorx,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,Yes,NA,NA
VNRX-7145 + ceftibuten,NA,Antibiotics,NA,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,NCT04243863,Venatorx,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,Yes,NA,NA
VNRX-7145 + ceftibuten,NA,Antibiotics,NA,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,NCT04243863,Venatorx,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,Yes,NA,NA
VNRX-7145 + ceftibuten,NA,Antibiotics,NA,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,NCT04243863,Venatorx,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,Yes,NA,NA
VNRX-7145 + ceftibuten,NA,Antibiotics,NA,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,NCT04243863,Venatorx,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,Yes,NA,NA
VNRX-7145 + ceftibuten,NA,Antibiotics,NA,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,NCT04243863,Venatorx,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,Yes,NA,NA
"XNW4107 +imipenem 
+ cilastin",NA,Antibiotics,NA,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,"NCT04802863, NCT04482569",Sinovent,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,No,NA,NA
"XNW4107 +imipenem 
+ cilastin",NA,Antibiotics,NA,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,"NCT04802863, NCT04482569",Sinovent,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,No,NA,NA
"XNW4107 +imipenem 
+ cilastin",NA,Antibiotics,NA,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,"NCT04802863, NCT04482569",Sinovent,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,NA,NA
"XNW4107 +imipenem 
+ cilastin",NA,Antibiotics,NA,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,"NCT04802863, NCT04482569",Sinovent,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,No,NA,NA
"XNW4107 +imipenem 
+ cilastin",NA,Antibiotics,NA,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,"NCT04802863, NCT04482569",Sinovent,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,No,NA,NA
"XNW4107 +imipenem 
+ cilastin",NA,Antibiotics,NA,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,"NCT04802863, NCT04482569",Sinovent,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,No,NA,NA
"XNW4107 +imipenem 
+ cilastin",NA,Antibiotics,NA,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,"NCT04802863, NCT04482569",Sinovent,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,No,NA,NA
"XNW4107 +imipenem 
+ cilastin",NA,Antibiotics,NA,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,"NCT04802863, NCT04482569",Sinovent,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,No,NA,NA
"XNW4107 +imipenem 
+ cilastin",NA,Antibiotics,NA,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,"NCT04802863, NCT04482569",Sinovent,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,No,NA,NA
"XNW4107 +imipenem 
+ cilastin",NA,Antibiotics,NA,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,"NCT04802863, NCT04482569",Sinovent,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Possibly,No,NA,NA
"XNW4107 +imipenem 
+ cilastin",NA,Antibiotics,NA,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,"NCT04802863, NCT04482569",Sinovent,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,No,NA,NA
"XNW4107 +imipenem 
+ cilastin",NA,Antibiotics,NA,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,"NCT04802863, NCT04482569",Sinovent,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Possibly,No,NA,NA
"XNW4107 +imipenem 
+ cilastin",NA,Antibiotics,NA,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,"NCT04802863, NCT04482569",Sinovent,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,No,NA,NA
YPT-01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04684641,Felix Biotechnology/ Yale University,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,NA,NA,NA
YPT-01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04684641,Felix Biotechnology/ Yale University,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,NA,NA,NA
YPT-01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04684641,Felix Biotechnology/ Yale University,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,NA,NA,NA
YPT-01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04684641,Felix Biotechnology/ Yale University,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,NA,NA,NA
YPT-01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04684641,Felix Biotechnology/ Yale University,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,NA,NA,NA
YPT-01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04684641,Felix Biotechnology/ Yale University,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,NA,NA,NA
YPT-01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04684641,Felix Biotechnology/ Yale University,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,NA,NA,NA
YPT-01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04684641,Felix Biotechnology/ Yale University,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,NA,NA,NA
YPT-01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04684641,Felix Biotechnology/ Yale University,Priority pathogens,Enterobacterales,Critical priority pathogens,NA,NA,NA,NA
YPT-01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04684641,Felix Biotechnology/ Yale University,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,NA,NA,NA
YPT-01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04684641,Felix Biotechnology/ Yale University,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,NA,NA,NA
YPT-01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04684641,Felix Biotechnology/ Yale University,Priority pathogens,All critical priority pathogens,Critical priority pathogens,NA,NA,NA,NA
YPT-01,NA,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,NCT04684641,Felix Biotechnology/ Yale University,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,NA,NA,NA,NA
Zidebactam + cefepime,NA,Antibiotics,NA,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,"NCT02532140, NCT02942810, NCT02707107",Wockhardt Ltd.,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,NA,No,NA,NA
Zidebactam + cefepime,NA,Antibiotics,NA,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,"NCT02532140, NCT02942810, NCT02707107",Wockhardt Ltd.,Priority pathogens,Staphylococcus aureus,Other priority pathogens,NA,No,NA,NA
Zidebactam + cefepime,NA,Antibiotics,NA,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,"NCT02532140, NCT02942810, NCT02707107",Wockhardt Ltd.,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,No,NA,NA
Zidebactam + cefepime,NA,Antibiotics,NA,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,"NCT02532140, NCT02942810, NCT02707107",Wockhardt Ltd.,Priority pathogens,Other priority pathogens,Other priority pathogens,NA,No,NA,NA
Zidebactam + cefepime,NA,Antibiotics,NA,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,"NCT02532140, NCT02942810, NCT02707107",Wockhardt Ltd.,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,NA,No,NA,NA
Zidebactam + cefepime,NA,Antibiotics,NA,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,"NCT02532140, NCT02942810, NCT02707107",Wockhardt Ltd.,Priority pathogens,Helicobacter pylori,Other priority pathogens,NA,No,NA,NA
Zidebactam + cefepime,NA,Antibiotics,NA,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,"NCT02532140, NCT02942810, NCT02707107",Wockhardt Ltd.,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,NA,No,NA,NA
Zidebactam + cefepime,NA,Antibiotics,NA,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,"NCT02532140, NCT02942810, NCT02707107",Wockhardt Ltd.,Priority pathogens,Enterococcus faecium,Other priority pathogens,NA,No,NA,NA
Zidebactam + cefepime,NA,Antibiotics,NA,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,"NCT02532140, NCT02942810, NCT02707107",Wockhardt Ltd.,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,No,NA,NA
Zidebactam + cefepime,NA,Antibiotics,NA,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,"NCT02532140, NCT02942810, NCT02707107",Wockhardt Ltd.,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,NA,NA
Zidebactam + cefepime,NA,Antibiotics,NA,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,"NCT02532140, NCT02942810, NCT02707107",Wockhardt Ltd.,Priority pathogens,Campylobacter spp.,Other priority pathogens,NA,No,NA,NA
Zidebactam + cefepime,NA,Antibiotics,NA,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,"NCT02532140, NCT02942810, NCT02707107",Wockhardt Ltd.,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Yes,No,NA,NA
Zidebactam + cefepime,NA,Antibiotics,NA,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,"NCT02532140, NCT02942810, NCT02707107",Wockhardt Ltd.,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,No,NA,NA
Zoliflodacin,NA,Antibiotics,NA,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,NCT03959527,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,No,Yes,NA,NA
Zoliflodacin,NA,Antibiotics,NA,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,NCT03959527,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Staphylococcus aureus,Other priority pathogens,No,Yes,NA,NA
Zoliflodacin,NA,Antibiotics,NA,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,NCT03959527,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,No,Yes,NA,NA
Zoliflodacin,NA,Antibiotics,NA,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,NCT03959527,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,Yes,NA,NA
Zoliflodacin,NA,Antibiotics,NA,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,NCT03959527,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,Yes,Yes,NA,NA
Zoliflodacin,NA,Antibiotics,NA,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,NCT03959527,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Helicobacter pylori,Other priority pathogens,No,Yes,NA,NA
Zoliflodacin,NA,Antibiotics,NA,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,NCT03959527,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,No,Yes,NA,NA
Zoliflodacin,NA,Antibiotics,NA,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,NCT03959527,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Enterococcus faecium,Other priority pathogens,No,Yes,NA,NA
Zoliflodacin,NA,Antibiotics,NA,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,NCT03959527,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Enterobacterales,Critical priority pathogens,No,Yes,NA,NA
Zoliflodacin,NA,Antibiotics,NA,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,NCT03959527,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Critical priority pathogens,Critical priority pathogens,No,Yes,NA,NA
Zoliflodacin,NA,Antibiotics,NA,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,NCT03959527,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Campylobacter spp.,Other priority pathogens,No,Yes,NA,NA
Zoliflodacin,NA,Antibiotics,NA,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,NCT03959527,Entasis Therapeutics Inc./ GARDP,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,Yes,NA,NA
Zoliflodacin,NA,Antibiotics,NA,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,NCT03959527,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,No,Yes,NA,NA
GSK3036656,GSK070,Antibiotics,NA,Leu RS inhibitor (oxaborole),Pulmonary tuberculosis,Oral,Phase II,NCT03557281,GlaxoSmithKline PLC,Mycobacterium tuberculosis,Mycobacterium tuberculosis,NA,NA,Yes,y,NA
BTZ-043,NA,Antibiotics,NA,DprE1 inhibitor (benzothiazinone),Tuberculosis,Oral,Phase II,"NCT03590600, NCT04044001","University of Munich; Hans Knöll Institute, Jena; German Center for Infection Research",Mycobacterium tuberculosis,Mycobacterium tuberculosis,NA,NA,Yes,y,NA
BVL-GSK098,NA,Non-traditional,Miscellaneous,"Amido piperidine (inactivation of TetR-like repressor, EthR2)",Tuberculosis,Oral,Phase I,NCT04654143,Bioversys/ GSK,Mycobacterium tuberculosis,Mycobacterium tuberculosis,NA,NA,NA,y,NA
Delpazolid,LCB01-0371,Antibiotics,NA,Oxazolidinone,"Pulmonary tuberculosis, Gram-positive bacterial infections",Oral,Phase II,"NCT02836483, NCT04550832","LegoChem Biosciences Inc., HaiHe Biopharma",Mycobacterium tuberculosis,Mycobacterium tuberculosis,NA,NA,No,y,NA
GSK2556286,GSK286,Antibiotics,NA,Undisclosed,Tuberculosis,Oral,Phase I,NCT04472897,GSK. TB Drug Accelarator/ Bill & Melinda Gates Foundation,Mycobacterium tuberculosis,Mycobacterium tuberculosis,NA,NA,Yes,y,NA
Macozinone,PBTZ-169,Antibiotics,NA,DprE1 inhibitor (Benzothiazinone),Pulmonary tuberculosis,Oral,Phase I,"NCT03036163, NCT03776500, NCT03334734",Innovative Medicines for Tuberculosis Foundation and Nearmedic Plus,Mycobacterium tuberculosis,Mycobacterium tuberculosis,NA,NA,Yes,y,NA
OPC-167832,NA,Antibiotics,NA,"DprE1 inhibitor (3,4-dihydrocarbostyril)",Pulmonary tuberculosis,Oral,Phase II,NCT03678688,"Otsuka Pharmaceutical Co., Ltd.",Mycobacterium tuberculosis,Mycobacterium tuberculosis,NA,NA,Yes,y,NA
Sutezolid,PNU-100480,Antibiotics,NA,Oxazolidinone,"Pulmonary tuberculosis, Gram-positive bacterial infections",Oral,Phase II,NCT03959566,TB Alliance/ Sequella,Mycobacterium tuberculosis,Mycobacterium tuberculosis,NA,NA,No,y,NA
TBA-7371,NA,Antibiotics,NA,DprE1 inhibitor (azaindole),Tuberculosis,Oral,Phase II,"NCT04176250, NCT03199339",TB Alliance/ Bill & Melinda Gates Medical Research Institute/ Foundation for Neglected Disease Research,Mycobacterium tuberculosis,Mycobacterium tuberculosis,NA,NA,Yes,y,NA
TBAJ-587,NA,Antibiotics,NA,Diarylquinoline,Tuberculosis,Oral,Phase I,NCT04890535,TB Alliance,Mycobacterium tuberculosis,Mycobacterium tuberculosis,NA,NA,No,y,NA
TBAJ-876,NA,Antibiotics,NA,Diarylquinoline,Tuberculosis,Oral,Phase I,NCT04493671,TB Alliance,Mycobacterium tuberculosis,Mycobacterium tuberculosis,NA,NA,No,y,NA
TBI-166,pyrifazimine,Antibiotics,NA,Riminophenazine (clofazimine-analogue),Tuberculosis,Oral,Phase I,NCT04670120,"Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College",Mycobacterium tuberculosis,Mycobacterium tuberculosis,NA,NA,No,y,NA
TBI-223,NA,Antibiotics,NA,Oxazolidinone,Tuberculosis,Oral,Phase I,"NCT03758612, NCT04865536",Institute of Materia Medica/ TB Alliance,Mycobacterium tuberculosis,Mycobacterium tuberculosis,NA,NA,No,y,NA
Telacebec,Q203,Antibiotics,NA,Imidazopyridine amide,Pulmonary tuberculosis,Oral,Phase II,"NCT03563599, NCT04847583",Qurient Co,Mycobacterium tuberculosis,Mycobacterium tuberculosis,NA,NA,Yes,y,NA
ART24,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,C. difficile infections,Oral,Phase I,NCT04891965,Artugen Therapeutics,Clostridioides difficile,Clostridioides difficile,NA,NA,NA,NA,y
BB128,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,Recurring C. difficile infections,Colonoscopy,Preregistration,NA,BiomeBank,Clostridioides difficile,Clostridioides difficile,NA,NA,NA,NA,y
CP101,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,Recurring C. difficile infections,Oral,Phase II,"NCT03110133, NCT03497806",Finch Theraputics,Clostridioides difficile,Clostridioides difficile,NA,NA,NA,NA,y
CRS3123,REP 3123,Antibiotics,NA,Diaryldiamine (Methionyl-tRNA synthetase inhibitor),C. difficile infections,Oral,Phase II,NCT04781387,Crestone/ National Institute of Allergy and Infectious Diseases,Clostridioides difficile,Clostridioides difficile,NA,NA,Yes,NA,y
DAV132,NA,Non-traditional,Microbiome-modulating agents,Antibiotic inactivator and protective colon-targeted adsorbent,C. difficile infections,Oral,Phase II,NCT03710694,Da Volterra,Clostridioides difficile,Clostridioides difficile,NA,NA,NA,NA,y
DNV3837,MCB-3837,Antibiotics,NA,Oxazolidinone-quinolone hybrid,C. difficile infections,IV,Phase II,NCT03988855,Deinove,Clostridioides difficile,Clostridioides difficile,NA,NA,Inconclusive,NA,y
Ibezapolstat,ACX-362E,Antibiotics,NA,Substituted guanine (DNA polymerae IIIIC inhibitor)),C. difficile infections,"Oral, Not absorbed",Phase II,NCT04247542,Acurx Pharmaceuticals,Clostridioides difficile,Clostridioides difficile,NA,NA,Yes,NA,y
IM-01,NA,Non-traditional,Antibodies,anti-C. difficile polcyclonal Ab,C. difficile infections,Oral,Phase II,NCT04121169,ImmuniMed,Clostridioides difficile,Clostridioides difficile,NA,NA,NA,NA,y
LMN-201,NA,Non-traditional,Bacteriophages and phage-derived enzymes,"Phage endolysin and three toxin-binding proteins (5D, E3, and 7F)s",C. difficile infections,Oral,Phase I,NCT04893239,Lumen Bioscience,Clostridioides difficile,Clostridioides difficile,NA,NA,NA,NA,y
MET-2,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,Recurring C. difficile infections,Oral,Phase I,"NCT02865616, NCT04602715",NuBiyota/ Takeda,Clostridioides difficile,Clostridioides difficile,NA,NA,NA,NA,y
MGB-BP-3,NA,Antibiotics,NA,DNA minor groove binder (distamycin),C. difficile-associated diarrhea,"Oral, Not absorbed",Phase II,NCT03824795,MGB Biopharma Ltd.,Clostridioides difficile,Clostridioides difficile,NA,NA,Yes,NA,y
RBX2660,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,C. difficile,Enema,Phase III,NCT03931941,Ferring Pharmaceuticals,Clostridioides difficile,Clostridioides difficile,NA,NA,NA,NA,y
RBX7455,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,Recurring C. difficile infections,Oral,Phase I,NCT02981316,Ferring (Rebiotix),Clostridioides difficile,Clostridioides difficile,NA,NA,NA,NA,y
Ridinilazole,SMT19969,Antibiotics,NA,Bis-benzimidazole,C. difficile infections,"Oral, Not absorbed",Phase III,"NCT02784002, NCT02092935, NCT03595553, NCT03595566, NCT04802837",Summit Therapeutics Inc.,Clostridioides difficile,Clostridioides difficile,NA,NA,Yes,NA,y
SER-109,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,C. difficile infections,Oral,Phase III,"NCT03183128, NCT03183141",Seres Theraputics,Clostridioides difficile,Clostridioides difficile,NA,NA,NA,NA,y
SYN-004,Ribaxamase,Non-traditional,Microbiome-modulating agents,Antibiotic inactivator,C. difficile infections,Oral,Phase II,"NCT02563106, NCT04692181",Synthetic Biologics,Clostridioides difficile,Clostridioides difficile,NA,NA,NA,NA,y
VE303,NA,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,Recurring C. difficile infections,Oral,Phase II,NCT03788434,Vedanta Biosciences,Clostridioides difficile,Clostridioides difficile,NA,NA,NA,NA,y
